REG - Tissue Regenix Group - Half-Year Trading Update and Notice of Results

Tissue RegenixAnnouncement

Yesterday 07:02

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250908:nRSH3532Ya&default-theme=true

RNS Number : 3532Y  Tissue Regenix Group PLC  08 September 2025

 Tissue Regenix Group plc

('Tissue Regenix' or the 'Group')

 

Half-Year Trading Update

and Notice of Results

 

Tissue Regenix (AIM: TRX), the regenerative medical devices company, provides
an unaudited trading update for the six months ended 30 June 2025.

 

Total Group revenue for the half year decreased by 6% to $13.8m (H1 2024:
$14.7m), driven by a decline in orders from the Company's strategic partners
due to uncertain economic conditions. The BioRinse portfolio experienced a
decline in sales in H1 2025 to $9.8m (H1 2024: $10.5m) due to the decline in
orders and ongoing delays in obtaining regulatory approval requirements
impacting the Group's ability to bring in new customers in new markets. Sales
for the dCELL® portfolio, dominated by the division's DermaPure® products,
overall decreased by 4% year-on-year (H1 2024: $4.2m) due to a decline in
orders from its strategic partner. However, revenue increased by 10%
year-on-year from its existing direct distribution network, which continues to
drive increased commercial activity through the addition of 32 new
distributors in H1 2025.

 

The Group expects to report a positive adjusted EBITDA for H1 2025, and the
Board remains confident of achieving profitability at the adjusted EBITDA
level for the full year in line with that achieved in FY 2024. Cash position
at 30 June 2025 remains sufficient to support the businesses current organic
growth plan and drive growth in 2026.

 

Jay LeCoque, Executive Chairman of Tissue Regenix, commented: "I'm pleased to
join Tissue Regenix as Executive Chairman at this important stage in its
development. While today's trading update shows that we have work to do, I am
confident in the strength of our people, our technology, and the market
opportunities ahead. My immediate priority is to work closely with Daniel and
the management team to sharpen our operational and commercial execution, with
a clear focus on driving sustainable, long-term earnings growth for our
shareholders."

 

Notice of Results

The Group will publish its interim results on Thursday 18 September 2025.

 

Investor Briefing

Daniel Lee, Chief Executive Officer, and Jay LeCoque, Executive Chairman, will
host a live online presentation relating to the interim results via the
Investor Meet Company platform at 16:00 BST on Thursday 18 September. The
presentation is open to all existing and potential shareholders.

 

Investors can sign up to Investor Meet Company for free and register for the
presentation here:

https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor
(https://www.investormeetcompany.com/tissue-regenix-group-plc/register-investor)

 

Investors who already follow Tissue Regenix on the Investor Meet Company
platform will be de facto invited.

 

For more information:

 

 Tissue Regenix Group plc                                           www.tissueregenix.com (http://www.tissueregenix.com)
 Daniel Lee, Chief Executive Officer                                via Walbrook PR

 Brandon Largent, Interim Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and Broker)
 Geoff Nash/Giles Balleny/Edward Whiley                             Tel: +44 (0) 20 7466 5000
 Nigel Birks - Life Science Specialist Sales
 Harriet Ward - ECM

 Walbrook PR (Financial PR and IR)                                  Tel: +44 (0)20 7933 8780
 Alice Woodings                                                     TissueRegenix@walbrookpr.com

The information contained within this announcement is deemed by the Company to
constitute inside information as stipulated under the Market Abuse Regulation
'MAR' EU no. 596/2014. Upon the publication of this announcement via the
Regulatory Information Service 'RIS', this inside information is now
considered to be in the public domain.

 

About Tissue Regenix (www.tissueregenix.com (http://www.tissueregenix.com) )

Tissue Regenix is a leading medical device company in regenerative medicine.
The Company's patented decellularisation technology (dCELL®) removes DNA and
other cellular material from animal and human soft tissue, leaving an
acellular tissue scaffold not rejected by the patient's body that can be used
to repair diseased or damaged body structures. Current applications address
many crucial clinical needs in sports medicine, foot and ankle injuries and
wound care.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTBIGDCRDGDGUR